FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
MB Number:	3235-0287				
stimated average burden					
ours per response	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)														
1. Name and Address of Reporting Person *- Cheong Kwang Soo				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]							JI	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
		(First) ARMACEUTICA ER DRIVE	ALS, INC., 9620	3. Date o			ansac	tion (Month	n/Day	v/Year)			re title below)		er (specify below	w)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)										up Filing(Chec	k Applicable Li	ne)
ROCKVILLE, MD 20850											-	_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Ci	ty)	(State)	(Zip)			Tal	ble I -	- Non-Deri	vativ	e Securities	Acquire	ed, Disposed	l of, or Ben	eficially Owr	ed	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		2A. Deemed Execution Date, if r) any (Month/Day/Year)		Date, if ((Instr. 8)		4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		of (D) O Tr		* *		6. Ownership Form: Direct (D) or Indirect	Beneficial Ownership		
							Coo	de V	Amoı	(A) or unt (D)	Price				I) Instr. 4)	
			ļ.	<u>. </u>		<u> </u>	Coo	de V	AIIIO	unt (D)	Price			J'	msu. 4)	
Reminder:	Report on a	separate line for eac	ch class of securities	s benefici	ally	owned d	irectl	Perso contai	ns w ned	tho respond in this form ays a curre	n are n	ot required	l to respor	id unless th		474 (9-02)
										of, or Benef rtible securi		Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	f Transaction of Code Derivr) (Instr. 8) Secur (A) o Dispo		Derivat Securiti Acquire (A) or Dispose	ive ies ed	Expiration	e Exercisable and ation Date th/Day/Year)		7. Title Amoun Underly Securiti (Instr. 3	t of ying ies		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersh Form of Derivativ Security: Direct (I or Indire	Ownershi y: (Instr. 4) D) ect
				Code	V	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amount or Number of Shares				
Stock Options (right to buy)	\$ 1.20							05/01/20	07 0	05/01/2016	Comm	20.000		20,000	D	
Stock Options (right to buy)	\$ 1.40							06/11/20	08 0	06/11/2017	Comm	170 000		20,000	D	
Stock Options (right to buy)	\$ 3.24							(1)	0	06/30/2018	Comm			20,000	D	
Stock Options (right to buy)	\$ 1.28	06/01/2009		A		20,000)	<u>(2)</u>	0	06/01/2019	Comm	20,000	\$ 0	20,000	D	

Reporting Owners

D / Add	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Cheong Kwang Soo C/O REXAHN PHARMACEUTICALS, INC. 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	X						

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for Kwang Soo Cheong	06/02/2009
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options vest and become exercisable in full on June 30, 2009.
- (2) These options vest and become exercisable in full on June 1, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.